Relative effectiveness assessment of listed drugs (REAL): A new method for an early comparison of the effectiveness of approved health technologies

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 124-130

  Falissard, Bruno ^a   Izard, Valérie ^b   Xerri, Bertrand ^b   Bouvenot, Gilles ^b   Meyer, Franois ^b   Degos, Laurent ^b  

^a University Paris South   (France)

^b Ancien Délégué Général de la Fédération de l'Hospitalisation Privée   (France)

Author keywords

Effect model; Effectiveness; Experts rating; Indirect comparisons; Mixed comparisons

Indexed keywords

ADDED VALUES; EFFECT MODEL; EFFECTIVENESS ASSESSMENT; ENGLAND; HEALTH TECHNOLOGY; MEDICAL TREATMENT; PARKINSON'S DISEASE; PRACTICAL PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TRANSPOSABILITY;

ENTACAPONE; PRAMIPEXOLE; RASAGILINE; ROTIGOTINE; PRESCRIPTION DRUG;

ARTICLE; DRUG EFFICACY; DRUG SCREENING; PARKINSON DISEASE; QUESTIONNAIRE; RELATIVE EFFECTIVENESS ASSESSMENT OF LISTED DRUGS; SENSITIVITY ANALYSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

COST-BENEFIT ANALYSIS; HUMANS; PRESCRIPTION DRUGS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 77949892852     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990821     Document Type: Article

References (24)

1. Agresti A. An introduction to categorical data analysis. New York: John Wiley & Sons; 1996.
2. Boissel JP, Collet JP, Lievre M, Girard P. An effect model for the assessment of drug benefit: Example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol. 1993;22:356-363.
3. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: Efficacy versus effectiveness studies? Ann Rheum Dis. 1999;58(Suppl 1):I82-I85.
4. Brannigan M. Oregon's experiment. Health Care Anal. 1993;1:15-32.
5. Danis M, Patrick DL, Southerland LI, Green ML. Patients' and families' preferences for medical intensive care. JAMA. 1988;260:797-802.
6. Davis CE. Generalizing from clinical trials. Control Clin Trials. 1994;15:11-14.
7. De Leeuw J. Unidimensional scaling. In: Everitt BS, Howell D, eds. Encyclopedia of statistics in behavioral science. New York: John Wiley & Sons; 2005.
8. Gelman A. Prior distributions for variance parameters in hierarchical models (Comment on an Article by Browne and Draper). Bayesian Anal. 2006;1:515-534.
9. Glenny AM, Altman DG, Song F, et al. International Stroke Trial Collaborative Group: Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1-134.
10. Harris J. It's not NICE to discriminate. J Med Ethics. 2005;31: 373-375.
11. Hill S, Garattini S, van Loenhout J, O'Brien BJ, de Joncheere K. Technology appraisal programme of the National Institute for Clinical Excellence: A review by WHO. World Health Organization; 2003.
12. La Puma J. Quality-adjusted life years: Ethical implications and the Oregon plan. Issues Law Med. 1992;7:429-441.
13. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262-1267.
14. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124.
15. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-2324.
16. National Institute for Clinical Excellence (NICE). Measuring effectiveness and cost effectiveness: The QALY. http://www. nice.org.uk/ newsevents/infocus/measuringeffectivenessandcost effectivenesstheQALY.jsp. Accessed October 17, 2008.
17. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513-520.
18. PricewaterhouseCoopers. Pharma 2020: The vision - Which path will you take? 2007; http://www.pwc.com/gx/eng/ about/ind/pharma. Accessed October 17, 2008.
19. Rascol O, Brooks DJ,Melamed E, et al.Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, doubleblind, parallel-group trial. Lancet. 2005;365:947-954.
20. Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): No(t yet an) exemplar of a deliberative process. J Med Ethics. 2008;34:534-539.
21. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17:1923-1942.
22. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003;326:472.
23. Thompson SG, Higgins JP. Treating individuals 4: Can meta-analysis help target interventions at individuals most likely to benefit? Lancet. 2005;365:341-346.
24. World Bank. Gross domestic product 2004. 2005. http://www. worldbank.org/.